[1] AL HT, HUSSEIN MH, AL MH, et al.Pathophysiology of IgA nephropathy[J].Adv Anat Pathol, 2017, 24(1):56. doi: 10.1097/PAP.0000000000000134
[2] YEO SC, CHEUNG CK, BARRATT J.New insights into the pathogenesis of IgA nephropathy[J].Pediatr Nephrol, 2018, 33(5):763. doi: 10.1007/s00467-017-3699-z
[3] KAWASAKI Y, MAEDA R, OHARA S, et al.Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy[J].Pediatr Int, 2018, 60(2):162. doi: 10.1111/ped.13461
[4] RIELLA MC.Kidney disease:Improving global outcomes (KDIGO) CKD work group.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Intern Suppl, 2013, 3(1):1. doi: 10.1038/kisup.2012.73
[5] LEE SM, RAO VM, FRANKLIN WA, et al.IgA nephropathy:morphologic predictors of progressive renal disease[J].Hum Pathol, 1982, 13(4):314. doi: 10.1016/S0046-8177(82)80221-9
[6] TRIMARCHI H, BARRATT J, CATTRAN DC, et al.Oxford Classification of IgA nephropathy 2016:an update from the IgA Nephropathy Classification Working Group[J].Kidney Int, 2017, 91(5):1014. doi: 10.1016/j.kint.2017.02.003
[7] KATAFUCHI R, KIYOSHI Y, OH Y, et al.Glomerular score as a prognosticator in IgA nephropathy:its usefulness and limitation[J].Clin Nephrol, 1998, 49(1):1.
[8] 郑爱萍, 侯霜, 罗明华, 等.IgA肾病患者系膜区C3沉积强度与临床病理特征的相关性分析[J].临床与实验病理学杂志, 2017, 33(12):1376.
[9] 杨柳.补体活化异常与IgA肾病[J].肾脏病与透析肾移植杂志, 2017, 26(3):273.
[10] CALISKAN Y, OZLUK Y, CELIK D, et al.The clinical significance of uric acid and complement activation in the progression of IgA nephropathy[J].Kidney Blood Press Res, 2016, 41(2):148. doi: 10.1159/000443415
[11] KIM SJ, KOO HM, LIM BJ, et al.Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy[J].PloS One, 2012, 7(7):e40495. doi: 10.1371/journal.pone.0040495
[12] 林淑芃.IgA肾病患者IgA1糖基化异常及其致病机制[J/CD].中华肾病研究电子杂志, 2015, 4(6): 316.
[13] 郑敬民, 尹广, 姚根宏, 等.肾病患者肾组织补体活化与肥大细胞浸润的关系研究[J].医学研究生学报, 2012, 25(10):1040.
[14] MADJENE LC, PONS M, DANELLI L, et al.Mast cells in renal inflammation and fibrosis:lessons learnt from animal studies[J].Mol Immunol, 2015, 63(1):86.
[15] 董福兴, 万建新.肥大细胞与补体C3的交互作用参与肾间质纤维化[J].中华肾脏病杂志, 2016, 32(2):158.
[16] ROJAS-RIVERA J, FERNáNDEZ-JUáREZ G, PRAGA M.Rapidly progressive IgA nephropathy:a form of vasculitis or a complement-mediated disease?[J].Clin Kidney J, 2015, 8(5):477. doi: 10.1093/ckj/sfv095
[17] YANG P, CHEN X, ZENG L, et al.The response of the Oxford classification to steroid in IgA nephropathy:a systematic review and meta-analysis[J].Oncotarget, 2017, 8(35):59748. doi: 10.18632/oncotarget.19574
[18] NASRI H, SAJJADIEH S, MARDANI S, et al.Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropath[J].J Nephropathol, 2013, 2(3):190. doi: 10.12860/JNP.2013.30
[19] 章晓炎, 谢静远, 王伟铭, 等.补体C3系膜区沉积与低C3血症在IgA肾病中的意义[J].中华肾脏病杂志, 2014, 30(3):187.
[20] 晏现丽, 张颖, 郑立运, 等.C3a、C5a受体缺失减轻IgA肾病肾损伤[J].中国免疫学杂志, 2015, 31(9):1169.
[21] 朱厉, 张宏.IgA肾病的精准医学研究进展:IgA肾病中补体系统的活化及临床意义[J].中华医学杂志, 2018, 98(14):1044.